Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) - Primary endpoint analysis of the CEBIFOX trial

被引：0

作者：

Kasper, S. ^{[1
]}

Meiler, J. ^{[1
]}

Knipp, H. ^{[2
]}

Hoehler, T. ^{[3
]}

Reimer, P. ^{[4
]}

Steinmetz, T. ^{[5
]}

Berger, W. ^{[6
]}

Linden, G. ^{[1
]}

Ting, S. ^{[7
]}

Markus, P. ^{[8
]}

Paul, A. ^{[9
]}

Dechene, A. ^{[10
]}

Kostbade, K. ^{[1
]}

Schuler, M. ^{[1
]}

Trarbach, T. ^{[1
]}

机构：

[1] Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol, Essen, Germany

[2] Alfried Krupp von Bohlen & Halbach Hosp, Dept Med 1, Essen, Germany

[3] Prosper Hosp, Dept Med 1, Recklinghausen, Germany

[4] Hosp Essen Werden, Dept Hematol & Med Oncol, Essen, Germany

[5] Grp Practice Hematol Oncol, Cologne, Germany

[6] Catholic Hosp, Dept Hematol & Med Oncol, Essen, Germany

[7] Univ Hosp Essen, West German Canc Ctr, Inst Pathol, Essen, Germany

[8] Elisabeth Hosp, Dept Gen Visceral & Trauma Surg, Essen, Germany

[9] Univ Hosp Essen, West German Canc Ctr, Dept Gen Visceral & Transplantat Surg, Essen, Germany

[10] Univ Hosp Essen, West German Canc Ctr, Dept Gastroenterol & Hepatol, Essen, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V328

引用

页码：99 / 100

页数：2

共 50 条

[1] Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) - an interim analysis of the CEBIFOX trial
Hoehler, T.
Decker, T.
Schimanski, C.
Schmitz, S.
Kanzler, S.
Rauh, J.
Vehling-Kaiser, U.
Bernhard, H.
Hoffmann, T.
Niederle, N.
von Verschuer, U.
von Wichert, G.
Wagner, T.
Klein, M.
ONKOLOGIE, 2013, 36 : 105 - 105
[2] Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC): Primary endpoint and subgroup analysis of the CEBIFOX trial
Kasper, Stefan
Meiler, Johannes
Knipp, Heike
Hoehler, Thomas
Reimer, Peter
Steinmetz, Tilman
Berger, Winfried
Linden, Gabriele
Ting, Saskia
Markus, Peter
Paul, Andreas
Dechene, Alexander
Schumacher, Brigitte
Kosbade, Karina
Worm, Karl
Schmid, Kurt Werner
Herold, Thomas
Schuler, Martin H.
Trarbach, Tanja
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[3] Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC): An interim analysis of the CEBIFOX trial.
Kasper, Stefan
Meiler, Johannes
Knipp, Heike
Hoehler, Thomas
Reimer, Peter
Steinmetz, Tilman
Berger, Winfried
Linden, Gabriele
Ting, Saskia
Markus, Peter
Paul, Andreas
Schuler, Martin H.
Trarbach, Tanja
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[4] Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) - Primary endpoint and subgroup analysis of the CEBIFOX trial
Kasper, S.
Meiler, J.
Knipp, H.
Hoehler, T.
Reimer, P.
Steinmetz, H. T.
Berger, W.
Linden, G.
Ting, S.
Markus, P.
Paul, A.
Dechene, A.
Schumacher, B.
Kostbade, K.
Worm, K.
Schmid, K. W.
Herold, T.
Schuler, M.
Trarbach, T.
ANNALS OF ONCOLOGY, 2016, 27
[5] Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial
Kasper, Stefan
Meiler, Johannes
Knipp, Heike
Hohler, Thomas
Reimer, Peter
Steinmetz, Tilman
Berger, Winfried
Linden, Gabriele
Reis, Henning
Markus, Peter
Paul, Andreas
Dechene, Alexander
Schumacher, Brigitte
Kostbade, Karina
Virchow, Isabel
Ting, Saskia
Worm, Karl
Schmid, Kurt W.
Herold, Thomas
Wiesweg, Marcel
Schuler, Martin
Trarbach, Tanja
CLINICAL COLORECTAL CANCER, 2020, 19 (04) : 236 - +
[6] COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB PLUS MFOLFOX6 VERSUS BEVACIZUMAB PLUS MFOLFOX6 FOR FIRST-LINE TREATMENT OF PATIENTS WITH WILD-TYPE RAS METASTATIC COLORECTAL CANCER
Graham, C. N.
Hechmati, G.
Hjelmgren, J.
De Liege, F.
Lanier, J.
Knoof, A.
Knox, H.
Barber, B.
de Pouvourville, G.
VALUE IN HEALTH, 2014, 17 (07) : A632 - A632
[7] Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
Graham, Christopher N.
Hechmati, Guy
Hjelmgren, Jonas
de Liege, Frederique
Lanier, Julie
Knox, Hediyyih
Barber, Beth
EUROPEAN JOURNAL OF CANCER, 2014, 50 (16) : 2791 - 2801
[8] Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.
Yoshino, Takayuki
Watanabe, Jun
Shitara, Kohei
Yasui, Hirofumi
Ohori, Hisatsugu
Shiozawa, Manabu
Yamazaki, Kentaro
Oki, Eiji
Sato, Takeo
Naitoh, Takeshi
Komatsu, Yoshito
Kato, Takeshi
Hihara, Masamitsu
Soeda, Junpei
Yamamoto, Kouji
Akagi, Kiwamu
Ochiai, Atsushi
Uetake, Hiroyuki
Tsuchihara, Katsuya
Muro, Kei
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
[9] Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
Rivera, Fernando
Valladares, Manuel
Gea, Salvador
Lopez-Martinez, Noemi
JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (06) : 574 - 584
[10] First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab or bevacizumab in patients with RAS/BRAF wild-type (WT) metastatic colorectal carcinoma (mCRC)
Rivera, F.
Karthaus, M.
Hecht, J. R.
Fasola, G.
Canon, J. -L.
Koukakis, R.
Demonty, G.
Schwartzberg, L.
ANNALS OF ONCOLOGY, 2015, 26

← 1 2 3 4 5 →